الفهرس 
Classificaion of fungOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
~Infection caused by Candida albicans and other related species
have increased in prevalence world wide. They range from mucosal
d iseases to fatal systemic. episodes in severely neutropenic subjects.
Since Candidiasis is almost always opponunisnc, it will recur in
many cases j f the llnderlyillg disease is not also treated.
Major development in researches into the azole class of
ami Itlllgal agents d uring the 1990s have provided expanded options
for the treatment of fungal ir1:f~tions as Candida. FulconazoJe has
proved to be safer than other antifungal agents. Despite these
advances, serious fungal infections remain difficult to treat, and
resistance to fluconazole is emerging.
In our study We compared the sensitivity of 40 isolates of
Candida [18 (45%) strain C. albicans, 12 (30%) C. tropical is,
4(10%) C. glabata, 4(10%) C. krusei and 2(5%) C. parapsilosis] to
fulconazole by using broth microdilution adaptation of the National
committee for clinical laboratory standards, Etest and Fungitest.
Candida species was defined by using germ tube test and CHROM
agar.
Etcst reading after 24 hrs and 48 hrs proved a highly
1itatistically significant difference in both sensitive, and resistant
cases but not in small dose dependent with p. value <0.001, <0.001
and 0.08 respectively.
-119-
SUMMAR’t AND CO,”iCLUS/UN
Results of 24 hrs incubation E test were found to have no
significant difference (p value 0.5) when compared with the
microdilution method. While the 48hs results had significant
difference (P. value <0.01).
It W3.’l found that there was no statistically significant
difference between Fungitest and microdilution method for all 40
isolates of Candida or for Candida albicans or Candida tropicalis (p.
value is 0.9, 0.8, 0.8 respectively).
Although both the E test and the Fungitest are promIsmg
alternatives tu the NeeLS reference broth microdilution method for
susceptibility testing of Candida to flunconazole. Further
development is necessary to standardize the medium and incubation
conditions, and test procedures before introduction of these as
routine methods in the clinical micorbiology laboratory for
suscepti bility testing.